Acarbose, calcium antagonists
The combined active ingredient with acarbose may cause hyperglycaemia, what may attenuate the acarbose effects. Monitorization of the blood-sugar concentration is recommended
ACE inhibitors, calcium antagonists
The co-administration may enhance the hypotensive effect
Acebutolol, calcium antagonists
Use acebutolol with great care with any other calcium antagonists, particularly diltiazem.
Adenosine [1], calcium antagonists ---> SmPC of [1] of eMC
Adenosine may interact with drugs tending to impair cardiac conduction.
Ajmaline, calcium antagonists
The combination of ajmaline with calcium antagonists may cause an additive inhibitory effect on the AV conduction, the intraventricular stimulus conduction and the force of contraction
Aldesleukin [1], calcium antagonists ---> SmPC of [1] of eMC
The co-administration may enhance the hypotension caused by aldesleukin.
Aminophylline [1], calcium antagonists ---> SmPC of [1] of eMC
Calcium channel blockers may decrease aminophylline clearance resulting in increased plasma theophylline concentrations and the potential for increased toxicity
Amlodipine/valsartan/hydrochlorothiazide [1], calcium antagonists ---> SmPC of [1] of EMA
Thiazides potentiate the antihypertensive action of other antihypertensive drugs
Antiarrhythmics, calcium antagonists
Calcium antagonist may potentiate the negative inotrope effect of antiarrthymics leading to sinus arrest and AV block
Antihypertensives, calcium antagonists
Diuretics potentiate the action of antihypertensive drugs
Atenolol/nifedipine, calcium antagonists
Atenolol/nifedipine may increase the blood pressure lowering and heart rate modulating effects of concomitant applied antihypertensives (other calcium antagonists)
Atracurium [1], calcium antagonists ---> SmPC of [1] of eMC
As with all non-depolarising neuromuscular blocking agents the magnitude and/or duration of a non-depolarising neuromuscular block may be increased as a result of interaction with calcium antagonists
Bendroflumethiazide, calcium antagonists
The co-administration may increase the antihypertensive effects
Betablockers, calcium antagonists ---> SmPC of [amlodipine] of eMC
Calcium channel blockers generally potentiate the pharmacologic effects of beta-blockers. Patients taking both agents should be carefully monitored for adverse cardiovascular events.
Betaxolol, calcium antagonists
The co-administration may cause additive effects resulting in hypotension, and/or marked bradycardia
Bicalutamide [1], calcium antagonists ---> SmPC of [1] of eMC
Caution should be used when administering bicalutamide (CYP3A4 inhibitor) with a calcium antagonist (metabolised by CYP3A4)
Bimatoprost/timolol [1], calcium antagonists ---> SmPC of [1] of EMA
There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral calcium channel blockers
Boceprevir [1], calcium antagonists ---> SmPC of [1] of EMA
Boceprevir, CYP3A4 inhibitor, may increase the plasma concentrations of calcium channel blocker. Caution is warranted and clinical monitoring of patients is recommended.
Buflomedil, calcium antagonists
The co-administration may increase the hypotensive effect
Bupivacaine, calcium antagonists
The co-administration may have an additive inhibitor effect on AV conduction, intraventricular impulse spread and contraction force
Calcitonin preparations, calcium antagonists
Dosage of the calcium antagonist may require adjustment in view of the fact that their effects may be modified by changes in cellular electrolyte concentrations
Calcium acetate [1], calcium antagonists ---> SmPC of [1] of eMC
The co-administration may decrease the effect of calcium antagonist
Calcium aminoethyl phosphate, calcium antagonists
The co-administration may decrease the effect of calcium antagonist
Calcium antagonists [1], chlortalidone ---> SmPC of [1] of eMC
Diuretics potentiate the action of antihypertensive drugs
Calcium antagonists, calcium aspartate
The co-administration may decrease the effect of calcium antagonist
Calcium antagonists, calcium chloride
Calcium-containing products may decrease the effectiveness of calcium channel blockers.
Calcium antagonists, calcium gluconate
Calcium-containing products may decrease the effectiveness of calcium channel blockers.
Calcium antagonists, calcium saccharate
The co-administration may decrease the effect of calcium antagonist
Calcium antagonists, captopril [2] ---> SmPC of [2] of eMC
Concomitant use of long-acting calcium antagonists and captopril may increase the hypotensive effects of captopril.
Calcium antagonists, carteolol [2] ---> SmPC of [2] of eMC
There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral calcium channel blockers
Calcium antagonists, cefixime
Increased bioavailability of cefixime
Calcium antagonists, celecoxib
Increased risk of acute renal insufficiency in patients with renal insufficiency
Calcium antagonists, cimetidine
Cimetidine delays the elimination of calcium antagonist and enhances or prolongs its effects and adverse effects (dose adjustment may be necessary)
Calcium antagonists, cisatracurium [2] ---> SmPC of [2] of eMC
Calcium antagonists increase the magnitude and/or duration of action of non-depolarising neuromuscular blocking agents
Calcium antagonists, clonazepam
Enhanced hypotensive effect
Calcium antagonists, clonidine [2] ---> SmPC of [2] of eMC
Concurrent administration of antihypertensive agents may lead to an increased hypotensive effect.
Calcium antagonists, cyclosporine
The co-administration may increase the cyclosporine plasma levels. Possible renal impairment
Calcium antagonists, CYP3A4 inductors
The CYP3A4 induction may decrease the plasma concentrations of the calcium antagonist
Calcium antagonists, CYP3A4 inhibitors
The CYP3A4 inhibition may increase the plasma concentrations of the calcium antagonist
Calcium antagonists, dantrolene ---> SmPC of [aliskiren/amlodipine] of EMA
Due to risk of hyperkalaemia, it is recommended that the co-administration of calcium channel blockers be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.
Calcium antagonists, dasabuvir with ombitasvir/paritaprevir/ritonavir ---> SmPC of [ombitasvir/paritaprevir/ritonavir]
Dose decrease and clinical monitoring of calcium channel blockers is recommended when coadministered with Viekirax with and without dasabuvir.
Calcium antagonists, daunorubicin
With concurrent administration of other cardioactive substances (e.g. calcium antagonists), an especially careful supervision of the heart function during the entire therapy is required.
Calcium antagonists, diazepam [2] ---> SmPC of [2] of eMC
Enhanced hypotensive effect
Calcium antagonists, diclofenac
Diclofenac may increase the elimination of the calcium channel blocker
Calcium antagonists, digitoxin
Serum levels of digitoxin may be increased by concomitant administration of calcium antagonists
Calcium antagonists, digoxin [2] ---> SmPC of [2] of eMC
Serum levels of digoxin may be increased by concomitant administration of calcium antagonists
Calcium antagonists, dihydralazine
The co-administration may increase the hypotensive effect
Calcium antagonists, dihydroergotamine
The effect of vasodilatador agents like nitrates or calcium antagonists may be decreased by dihydroergotamine
Calcium antagonists, dorzolamide/timolol [2] ---> SmPC of [2] of eMC
There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic betablockers solution is administered concomitantly with oral calcium channel blockers
Calcium antagonists, doxorubicine [2] ---> SmPC of [2] of eMC
Doxorubicin cardiotoxicity is enhanced by previous or concurrent use of other potentially cardiotoxic drugs. When doxorubicin is used together, cardiac function must be followed carefully.
Calcium antagonists, dronedarone [2] ---> SmPC of [2] of EMA
The CYP3A4 inhibition may increase the exposition of calcium antagonist. In patients already on calcium antagonists at time of dronedarone initiation, an ECG should be performed and the calcium antagonist dose should be adjusted if needed
Calcium antagonists, elcatonin
Dosage of the calcium antagonist may require adjustment in view of the fact that their effects may be modified by changes in cellular electrolyte concentrations
Calcium antagonists, epirubicin [2] ---> SmPC of [2] of eMC
The concomitant use of epirubicin with cardioactive compounds (e.g., calcium channel blockers) requires monitoring of cardiac function throughout treatment
Calcium antagonists, erythromycin
The macrolide inhibits the CYP3A4 and therefore may increase the plasma concentrations of calcium antagonist. Azithromycin is void of CYP3A4 inhibition.
Calcium antagonists, esmolol [2] ---> SmPC of [2] of eMC
Calcium antagonists may increase the risk of hypotension. In patients with cardiac insufficiency and who are being treated with a calcium antagonist, treatment with beta-blocking agents may lead to cardiac failure.
Calcium antagonists, etilefrine
The vasodilatator effect of vasodilator drugs may be weaken
Calcium antagonists, fingolimod [2] ---> SmPC of [2] of EMA
Treatment with Gilenya should not be initiated in patients receiving beta blockers, or other substances which may decrease heart rate because of the potential additive effects on heart rate
Calcium antagonists, flecainide [2] ---> SmPC of [2] of eMC
The use of flecainide with calcium channel blockers, e.g. verapamil, should be considered with caution.
Calcium antagonists, fluconazole [2] ---> SmPC of [2] of eMC
Certain calcium channel antagonists are metabolized by CYP3A4. Fluconazole has the potential to increase the systemic exposure of the calcium channel antagonists.
Calcium antagonists, fosinopril [2] ---> SmPC of [2] of eMC
Combination with of fosinopril with other anti-hypertensive agents may increase the anti-hypertensive effect.
Calcium antagonists, gadoteric acid
Decreased efficacy of cardiovascular compensation mechanisms that occur in blood pressure disorder
Calcium antagonists, general anesthetics [2] ---> SmPC of [2] of eMC
Depression of cardiac contractility, conductivity and automaticity, as well as the vascular dilatation associated with anaesthetics may be potentiated by calcium channel blockers.
Calcium antagonists, glibenclamide [2] ---> SmPC of [2] of EMA
Weakening of the blood-glucose-lowering effect
Calcium antagonists, glycerol trinitrate
Treatment with other agents with hypotensive effects may potentiate the hypotensive effect of glyceryl trinitrate.
Calcium antagonists, glycerol trinitrate [2] ---> SmPC of [2] of eMC
Treatment with other agents with hypotensive effects may potentiate the hypotensive effect of glyceryl trinitrate.
Calcium antagonists, guanethidine
The anti-hypertensive action of guanethidine may be enhanced by other anti-hypertensive agents.
Calcium antagonists, halogenated anaesthetics ---> SmPC of [verapamil] of eMC
Caution should be exercised when calcium antagonists are used concomitantly with inhalation anaesthetics due to the risk of additive negative inotropic effect.
Calcium antagonists, hydralazine
The co-administration may increase the hypotensive effect
Calcium antagonists, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA
Thiazides potentiate the antihypertensive action of other antihypertensive drugs
Calcium antagonists, idarubicin [2] ---> SmPC of [2] of eMC
The use of idarubicin in combination chemotherapy with other cardioactive compounds requires monitoring of cardiac function throughout treatment.
Calcium antagonists, iloprost [2] ---> SmPC of [2] of EMA
Iloprost may increase the effects of vasodilatators and antihypertensive agents and then favour the risk of hypotension
Calcium antagonists, imatinib [2] ---> SmPC of [2] of EMA
Glivec may increase plasma concentration of other CYP3A4 metabolised drugs (e.g. triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, i.e. statins, etc.).
Calcium antagonists, interleukin-2 [2] ---> SmPC of [2] of eMC
The co-administration may enhance the hypotension caused by aldesleukin.
Calcium antagonists, irbesartan [2] ---> SmPC of [2] of EMA
Other antihypertensive agents may increase the hypotensive effects of irbesartan; however Aprovel has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics.
Calcium antagonists, isoflurane [2] ---> SmPC of [2] of eMC
Calcium antagonists, in particular dihydropyridine derivates: isoflurane may lead to marked hypotension in patients treated with calcium antagonists.
Calcium antagonists, isosorbide dinitrate [2] ---> SmPC of [2] of eMC
Concurrent intake of drugs with blood pressure lowering properties may potentiate the hypotensive effect
Calcium antagonists, isosorbide mononitrate
The co-administration may potentiate the antihypertensive effect of isosorbide mononitrate and cause orthostatic dysregulation
Calcium antagonists, itraconazol [2] ---> SmPC of [2] of eMC
Calcium channel blockers can have negative inotropic effects which may be additive to those of itraconazole. In addition, itraconazole can inhibit the metabolism of calcium channel blockers.
Calcium antagonists, laropiprant/nicotinic acid [2] ---> SmPC of [2] of EMA
Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive medicinal products such as nitrates, calcium channel blockers, and adrenergic receptor blocking agents, resulting in postural hypotension.
Calcium antagonists, latanoprost/timolol [2] ---> SmPC of [2] of eMC
There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral calcium channel blockers
Calcium antagonists, levacetylmethadol
Medicinal products for the treatment of angina, high blood pressure or an irregular heart beat are contraindicated with levacetylmethadol
Calcium antagonists, levobunolol [2] ---> SmPC of [2] of eMC
There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blocker solutions are administered concomitantly with oral calcium channel blockers
Calcium antagonists, liposome-encapsulated doxorubicin-citrate complex [2] ---> SmPC of [2] of EMA
Concomitant treatment of doxorubicine with other substances reported to be cardiotoxic or with cardiologically active substances (e.g. calcium antagonists) may increase the risk for cardiotoxicity.
Calcium antagonists, lithium
Calcium channel blockers may lead to neurotoxicity with symptoms such as ataxia, confusion and somnolence. Lithium concentrations may be increased.
Calcium antagonists, lithium carbonate [2] ---> SmPC of [2] of eMC
Calcium channel blockers may lead to neurotoxicity with symptoms such as ataxia, confusion and somnolence. Lithium concentrations may be increased.
Calcium antagonists, lorazepam [2] ---> SmPC of [2] of eMC
Enhanced hypotensive effect
Calcium antagonists, macrolide antibiotics
The macrolide inhibits the CYP3A4 and therefore may increase the plasma concentrations of calcium antagonist. Azithromycin is void of CYP3A4 inhibition.
Calcium antagonists, mefloquine
Concomitant administration of mefloquine and other drugs known to alter cardiac conduction might contribute to a prolongation of the QTc interval.
Calcium antagonists, mepivacaine
The co-administration may have an additive inhibitory effect on AV conduction, intraventricular impulse spreading and contraction force
Calcium antagonists, metformin
Decreased hypoglycemic effect
Calcium antagonists, methyldopa
Concomitant use of methyldopa and calcium-channel blockers may enhance the hypotensive effect.
Calcium antagonists, metildigoxin
Increased plasma levels of metildigoxin
Calcium antagonists, midazolam
Enhanced hypotensive effect
Calcium antagonists, mifamurtide
Caution should be exercised when starting concomitant use of mifamurtide with antihypertensives and patients should be monitored for possible adverse reactions.
Calcium antagonists, milrinone [2] ---> SmPC of [2] of eMC
Whilst there is a theoretical potential interaction with calcium channel blockers, there has been no evidence of a clinically significant interaction to date.
Calcium antagonists, mivacurium [2] ---> SmPC of [2] of eMC
As all non-depolarising neuromuscular blocking agents, the magnitude and/or duration of non-depolarising neuromuscular block may be increased and infusion requirements may be reduced as a result of interaction with calcium channel blockers
Calcium antagonists, molsidomine
The co-administration may potentiate the hypotensive effect
Calcium antagonists, muscle relaxants
The duration and intensity of action of muscle relaxants may be enhanced.
Calcium antagonists, muscle relaxants (non-depolarizing) ---> SmPC of [atracurium] of eMC
As with all non-depolarising neuromuscular blocking agents the magnitude and/or duration of a non-depolarising neuromuscular block may be increased as a result of interaction with calcium antagonists
Calcium antagonists, nadolol [2] ---> SmPC of [2] of eMC
Calcium channel blockers generally potentiate the pharmacologic effects of beta-blockers. Patients taking both agents should be carefully monitored for adverse cardiovascular events.
Calcium antagonists, neuroleptics
The hypotensive effect of calcium channel blockers is enhanced by concurrent use of antipsychotic drugs.
Calcium antagonists, nicorandil [2] ---> SmPC of [2] of eMC
If nicorandil is used concomitantly with antihypertensive agents or other medicinal products with blood-pressure-lowering effect the blood-pressure-lowering effect may be increased.
Calcium antagonists, nicotinic acid
Nicotinic acid may potentiate the blood-pressure lowering effect
Calcium antagonists, nifedipine [2] ---> SmPC of [2] of eMC
Nifedipine may be used in combined therapy with other antihypertensive agents including beta-blocker drugs, but the possibility of an additive effect resulting in postural hypotension should be borne in mind.
Calcium antagonists, nimodipine [2] ---> SmPC of [2] of eMC
Nimodipine may increase the blood pressure lowering effect of concomitant antihypertensives
Calcium antagonists, nisoldipine
The co-administration may potentiate the hypotensive effect
Calcium antagonists, nitrendipine
The co-administration may potentiate the hypotensive effect
Calcium antagonists, nitroglycerine [2] ---> SmPC of [2] of eMC
Treatment with other agents with hypotensive effects may potentiate the hypotensive effect of glyceryl trinitrate.
Calcium antagonists, ombitasvir/paritaprevir/ritonavir [2] ---> SmPC of [2] of EMA
Dose decrease and clinical monitoring of calcium channel blockers is recommended when coadministered with Viekirax with and without dasabuvir.
Calcium antagonists, oxprenolol [2] ---> SmPC of [2] of eMC
Calcium antagonists may enhance bradycardia, myocardial depression and hypotension; particularly after i.v. use of verapamil in patients taking oral betablockers, the possibility of hypotension and cardiac arrhythmias cannot be excluded
Calcium antagonists, ozanimod [2] ---> SmPC of [2] of EMA
Caution should be applied when ozanimod is initiated in patients receiving treatment with a betablocker or a calcium-channel blocker (e.g. diltiazem and verapamil) because of the potential for additive effects on lowering HR.
Calcium antagonists, pancuronium [2] ---> SmPC of [2] of eMC
As with all non-depolarising neuromuscular blocking agents the magnitude and/or duration of a non-depolarising neuromuscular block may be increased as a result of interaction with calcium antagonists
Calcium antagonists, PDE5 inhibitors
The combination may increase the hypotensive effect
Calcium antagonists, pentaerythritol tetranitrate
The co-administration may potentiate the hypotensive effect
Calcium antagonists, perindopril
The co-administration may enhance the hypotensive effect
Calcium antagonists, phenazone
Concomitant use of phenazone and calcium antagonists delays the elimination of phenazone. There is the possibility of an accumulation
Calcium antagonists, pimozide [2] ---> SmPC of [2] of eMC
Concomitant use of pimozide with calcium channel blockers may result in an enhanced hypotensive effect.
Calcium antagonists, pioglitazone ---> SmPC of [pioglitazone/metformin] of EMA
Interactions with substances metabolised by these enzymes (see cytochrome P450), e.g. oral contraceptives, cyclosporin, calcium channel blockers, and HMGCoA reductase inhibitors are not to be expected.
Calcium antagonists, pioglitazone/metformin [2] ---> SmPC of [2] of EMA
Interactions with substances metabolised by these enzymes (see cytochrome P450), e.g. oral contraceptives, cyclosporin, calcium channel blockers, and HMGCoA reductase inhibitors are not to be expected.
Calcium antagonists, porfimer [2] ---> SmPC of [2] of EMA
Possible interaction with the photodynamic therapy
Calcium antagonists, prajmalium
With the co-administration of prajmalium with calcium antagonists is to expect an additive inhibitor effect on the AV-conduction, intraventricular conduction and contraction force
Calcium antagonists, procaine
The co-administration may have an additive inhibiting effect on the AV conduction, intraventricular impulse spread and contractile force
Calcium antagonists, propafenone
The co-administration may enhance the propafenone effect and cause cardiodepressant effects
Calcium antagonists, propranolol
Calcium antagonists and betablockers may have additive effects on the AV conduction and sinoatrial nodal function and cause bradycardia and hypotension. The combination with propranolol should be avoided
Calcium antagonists, quinidine
Calcium antagonist may potentiate the negative inotrope effect of antiarrthymics leading to sinus arrest and AV block
Calcium antagonists, ranitidine
Ranitidine can increase the calcium antagonist plasma level
Calcium antagonists, recombinant salmon calcitonin [2] ---> SmPC of [2] of EMA
Care should be exercised in patients receiving concurrent treatment of calcitonin with calcium channel blocking agents. Dosages of these drugs may require adjustment
Calcium antagonists, remifentanil [2] ---> SmPC of [2] of eMC
The cardiovascular effects of remifentanil (hypotension and bradycardia), may exacerbate in patients receiving concomitant cardiac depressant drugs
Calcium antagonists, rifampicin [2] ---> SmPC of [2] of eMC
Rifampicin is a potent inducer of certain cytochrome P-450 enzymes. Coadministration of rifampicin with drugs that are also metabolised through these cytochrome P-450 enzymes may accelerate the metabolism and reduce the activity of these other drugs.
Calcium antagonists, ritonavir [2] ---> SmPC of [2] of EMA
Possible increase in the plasma concentrations of calcium channel antagonist. Careful monitoring of therapeutic and adverse effects is recommended.
Calcium antagonists, rivastigmine [2] ---> SmPC of [2] of EMA
Caution should be exercised when rivastigmine is combined with beta-blockers and also other bradycardia agents
Calcium antagonists, rocuronium [2] ---> SmPC of [2] of eMC
Increased rocuronium effects
Calcium antagonists, saquinavir/ritonavir ---> SmPC of [saquinavir] of EMA
Possible increase in the plasma concentrations of calcium channel antagonist. Careful monitoring of therapeutic and adverse effects is recommended.
Calcium antagonists, sildenafil [2] ---> SmPC of [2] of EMA
Population pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics when grouped as calcium channel blockers
Calcium antagonists, spironolactone
The co-administration may cause severe hyperkalaemia
Calcium antagonists, stiripentol [2] ---> SmPC of [2] of EMA
Stiripentol is an inhibitor of the enzymes CYP3A4 and may markedly increase the plasma concentrations of substances metabolised by these enzymes and increase the risk of adverse reactions
Calcium antagonists, strong CYP3A4 inductors
The strong CYP3A4 induction may decrease the plasma concentrations of the calcium antagonist
Calcium antagonists, strong CYP3A4 inhibitors
The strong CYP3A4 inhibition may increase the plasma concentrations of the calcium antagonist
Calcium antagonists, succinylcholine
The co-administration may enhance the neuromuscular blocking action of suxamethonium
Calcium antagonists, suxamethonium
The co-administration may enhance the neuromuscular blocking action of suxamethonium
Calcium antagonists, tadalafil [2] ---> SmPC of [2] of EMA
Tadalafil (10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose was applied) had no clinically significant interaction
Calcium antagonists, temsirolimus [2] ---> SmPC of [2] of EMA
Caution should be exercised when temsirolimus is given concomitantly with ACE inhibitors (e.g. ramipril) and/or calcium channel blockers (e.g. amlodipine). An increased risk of angioneurotic oedema is possible
Calcium antagonists, theophylline [2] ---> SmPC of [2] of eMC
Calcium antagonists reduce clearance of theophylline and a reduced dosage may therefore be necessary to avoid side-effects
Calcium antagonists, thiazides ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA
Thiazides potentiate the antihypertensive action of other antihypertensive drugs
Calcium antagonists, thiopental
Thiopental will interact with beta-blockers causing a fall in blood pressure.
Calcium antagonists, timolol ---> SmPC of [bimatoprost/timolol] of EMA
There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral calcium channel blockers
Calcium antagonists, tocilizumab [2] ---> SmPC of [2] of EMA
When starting or stopping therapy with tocilizumab, patients taking medicinal products which are individually adjusted and are metabolised via CYP450 3A4, 1A2 or 2C9 should be monitored as doses may need to be increased to maintain therapeutic effect.
Calcium antagonists, travoprost/timolol [2] ---> SmPC of [2] of EMA
The potential exists for additive effects and production of hypotension and/or marked bradycardia.
Calcium antagonists, triamterene [2] ---> SmPC of [2] of eMC
The co-administration of triamterene and calcium-channel blockers may enhance the hypotensive effect
Calcium antagonists, tricyclic antidepressant
Possible increase of plasma levels and toxicity of tricyclic antidepressant
Calcium antagonists, verteporfin [2] ---> SmPC of [2] of EMA
The co-administration may enhance the verteporfin tissue-uptake
Calcium antagonists, vincristine
The co-administration may decrease the plasma clearance of vincristine and increase the toxicity risk
Calcium antagonists, zofenopril
Additive or enhanced hypotension may occur
Calcium channel blockers metabolised through CYP3A4, posaconazole [2] ---> SmPC of [2] of EMA
Concomitant use of posaconazole with calcium channel blockers metabolised through CYP3A4 increases plasma concentrations of the calcium channel blocker.
Calcium, calcium antagonists [2] ---> SmPC of [2] of eMC
Calcium-containing products may decrease the effectiveness of calcium channel blockers.